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Abstract
Background and objectives—In 2011, the U.S. Secretary of Health and Human Services 
recommended universal screening of newborns for critical congenital heart defects (CCHD), yet 
few estimates of the number of infants with CCHD likely to be detected through universal 
screening exist. Our objective was to estimate the number of infants with nonsyndromic CCHD in 
the United States likely to be detected (true positives) and missed (false negatives) through 
newborn CCHD screening.
Methods—We developed a simulation model based on estimates of birth prevalence, prenatal 
diagnosis, late detection, and sensitivity of newborn CCHD screening through pulse oximetry to 
estimate the number of true positive and false negative nonsyndromic cases of the seven primary 
and five secondary targets of CCHD screening identified through screening.
Results—We estimated that 875 (95% uncertainty interval [UI]: 705–1,060) U.S. infants with 
nonsyndromic CCHD, including 470 (95% UI: 360–585) among primary CCHD screening targets, 
will be detected annually through CCHD newborn screening. An additional 880 (UI: 700–1,080) 
false negative screenings, including 280 (95% UI: 195–385) among primary screening targets, are 
expected. We estimated that similar numbers of CCHD (within ~1 case/10,000 live births) would 
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be detected under scenarios comparing “lower” (~19%) and “higher” (~42%) than current prenatal 
detection prevalences.
Conclusions—A substantial number of nonsyndromic CCHD cases are likely to be detected 
through universal CCHD screening; however, an equal number of false negative screenings, 
primarily among secondary targets of screening, are likely to occur. Future efforts should 
document the true impact of CCHD screening in practice.
Keywords
heart defects; congenital; neonatal screening; Monte Carlo methods
INRODUCTION
Congenital heart defects (CHD) affect ~8/1,000 births and ~25% are considered critical 
congenital heart defects (CCHD).1 In 2011 the U.S. Secretary of Health and Human 
Services recommended adding CCHD to the newborn Recommended Uniform Screening 
Panel.2 Subsequently, screening for CCHD through pulse oximetry, used to supplement 
standard clinical evaluation and monitoring of newborns, has been implemented in many 
hospitals.3–5 Screening protocols vary regarding the age of the newborn at screening and the 
use of pre- and/or post-ductal oxygen saturation measurements.4,6 The American Academy 
of Pediatrics (AAP), American Heart Association (AHA), and others recommend screening 
infants at 24–48 hours of life with consideration of both pre- and post-ductal 
measurements.7
Estimates of the impact of CCHD screening differ.4,8,9 Differences in prenatal diagnosis and 
“late” detection (i.e., CCHD diagnosis after birth hospital discharge9 or after three days of 
life8) by CCHD type and geographic location might contribute to the observed 
variation.8,10–12 Another potential contributor is the sensitivity of the pulse oximetry 
screening test; although the overall sensitivity is estimated to be 76%,13 it varies 
considerably by CCHD type, ranging from 36–100%.14
Estimating the number of infants potentially detected (“true positives”) and missed (“false 
negatives”) through universal CCHD screening must incorporate three key sources of 
variability: (1) the birth prevalence of the specific CCHD; (2) the prenatal diagnosis 
prevalence, both across CCHD types and geographic region; and (3) the sensitivity of 
CCHD screening for different CCHD types. This study incorporated these elements into a 
simulation model to estimate the number of true positive and false negative CCHD cases in 
the United States likely to occur through CCHD screening using pulse oximetry.
PATIENTS AND METHODS
We included the seven CCHD considered to be “primary” targets of screening: hypoplastic 
left heart syndrome (HLHS), pulmonary atresia, dextro-transposition of the great arteries (d-
TGA), truncus arteriosus, tricuspid atresia, tetralogy of Fallot (TOF), and total anomalous 
pulmonary venous return (TAPVR).7 We also included the five “secondary” targets of 
CCHD screening: coarctation of the aorta (COA), double-outlet right ventricle (DORV), 
Ebstein anomaly, interrupted aortic arch (IAA), and single ventricle.1 While critical aortic 
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and pulmonary stenoses are also typically considered CCHD, we lacked complete data on 
lesion severity.15 We combined COA and IAA into one category (COA/IAA) as this was 
done for one of our data sources.14 To calculate estimates for “all CCHD” by summing 
across the specific CCHD estimates, we created a “multiple CCHD” category including 
those cases with multiple CCHD diagnoses, such that no case was counted more than once. 
We restricted the analysis to infants with CCHD diagnosed before 1 year of life. To better 
reflect the population of infants eligible for CCHD screening, all analyses were restricted to 
liveborn infants, and, for consistency across data sources, restricted to infants without 
chromosomal abnormalities (“nonsyndromic”).
Live Birth Prevalence
We simulated a 2012 birth cohort of infants with nonsyndromic CCHD using data from the 
Metropolitan Atlanta Congenital Defects Program (MACDP), an active surveillance system 
for major birth defects in metropolitan Atlanta, Georgia.16 Surveillance is conducted for 
infants, fetuses, and stillbirths >20 weeks gestation with major birth defects identified before 
six years of age. Trained abstractors visit birth hospitals, pediatric hospitals, specialty clinics 
and perinatal offices to identify and abstract clinical and demographic information on 
potential cases. CHD cases are classified by clinicians with expertise in pediatric 
cardiology.17 For our analysis, we updated Oster et al.’s (2013)15 analysis to calculate the 
2000–2005 live birth prevalence of the 12 selected CCHD types.
Frequency of Prenatal Diagnosis
Prenatal diagnosis was estimated using data from the National Birth Defects Prevention 
Study (NBDPS), a multisite case-control study of risk factors for select major birth defects, 
including CCHD.18 Cases were identified through birth defects surveillance systems in ten 
U.S. sites; infants with recognized or strongly suspected single gene disorders or 
chromosomal abnormalities were excluded. Trained abstractors reviewed medical records of 
infants/fetuses with CCHD and, to be included in the study, CCHD cases had to be 
confirmed by echocardiography, cardiac catheterization, surgery, or autopsy.18 Prenatally 
diagnosed cases were only included if confirmed by autopsy or by a clinician with expertise 
in pediatric cardiology.19 CCHD type(s) were assigned by physicians with specialized 
training in clinical genetics or pediatric cardiology.19 We defined prenatal diagnosis as 
either: 1) a maternal report of a prenatal diagnosis of a CHD (as had been done in a previous 
analysis10) and/or 2) clinical record of a fetal echocardiography before the date of birth. 
Then, for each CCHD type, we calculated the 2000–2005 prenatal diagnosis prevalence.
Frequency of Late Detection
NBDPS data were also used to estimate the prevalence of “late” CCHD detection.8 
Previously, we categorized infants with echocardiography or autopsy information as having 
“timely” CCHD detection if their first documented echocardiography was within three days 
of birth and as having “late” CCHD detection if their first echocardiography (or autopsy) 
occurred after the third day of life.8 Here, we modified the analysis slightly to be restricted 
to infants without a prenatal diagnosis (as defined above). We calculated the 2000–2005 late 
detection prevalence among live-born infants without a prenatal diagnosis.
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Sensitivity of Newborn CCHD Screening Through Pulse Oximetry
We obtained CCHD-specific estimates of the sensitivity of screening through pulse oximetry 
from a review by Prudhoe et al., which used mutually-exclusive CCHD categories but did 
not provide estimates for Ebstein anomaly or “multiple CCHD”.14 We summed the number 
of cases reported to be detected through CCHD screening using pulse oximetry and the total 
number of cases screened, across all secondary screening targets, to obtain an estimate of 
screening sensitivity for Ebstein anomaly, and across all CCHD, to obtain an estimate for 
multiple CCHD.
Analysis
For each CCHD, we estimated the number of true positive and false negative cases resulting 
from CCHD screening through pulse oximetry (Figure 1). To account for uncertainty in our 
birth prevalence, prenatal diagnosis, late detection, and CCHD screening sensitivity for each 
CCHD type, we used normal distributions based on the reported estimated means and 
standard errors for these parameters (Table 1). However, there were four estimates of CCHD 
screening sensitivity that were based on exceptionally small numbers (≤ 10 total cases) and, 
for three of them, there was no sample variance associated with the estimate. For these 
parameters, we used a uniform distribution based on the lower and upper 95% confidence 
limits of the Wilson Score exact 95% confidence interval (Table 1). We then used a Monte 
Carlo simulation approach and drew 10,000 samples from the distributions of each of the 
parameter estimates, as described above. For each simulation, to avoid negative values, 
simulated values were truncated with a lower bound at zero cases. We summarized the 
results of the 10,000 simulations using the mean and a 95% uncertainty interval (UI) defined 
by the 2.5th and 97.5th percentiles of the distribution of simulated values. Because we had 
created mutually exclusive CCHD categories throughout the analysis, for each simulation 
we calculated the sum of each parameter of interest and summarized the results of the 
simulation using the same statistics (mean, 95% UI) to obtain our estimates for “all CCHD”. 
To further reflect uncertainty in our estimates, we rounded estimates to the nearest five 
cases.
As a secondary analysis, we repeated the analysis under scenarios of “lower” and “higher” 
prevalence of prenatal diagnosis than the current estimates. Using NBDPS data, we 
identified the three sites with the highest and three with the lowest prevalence of prenatal 
detection. We calculated the prevalence of prenatal diagnosis and late detection within each 
of these sub-groups and used them as separate inputs into our simulation model, while 
keeping the same estimates for birth prevalence and CCHD screening sensitivity as in the 
primary analysis.
Analyses were performed using SAS, v.9.3 (SAS Institute, Cary, NC). MACDP was 
approved by the Institutional Review Board (IRB) at the Center for Disease Control and 
Prevention (CDC) and NBDPS by IRBs at the CDC and study sites.
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As inputs for our simulation, we estimated that the 2000–2005 live birth prevalence for 
specific nonsyndromic CCHD ranged from 0.36 (0.11) per 10,000 births for multiple CCHD 
to 3.90 (0.36) per 10,000 births for TOF (Table 1). Prenatal diagnosis was most frequent for 
HLHS and single ventricle and lowest for TAPVR and COA/IAA. Late detection (diagnosis 
at >3 days of birth) was more common for infants with COA/IAA and less frequent for 
infants with pulmonary atresia and d-TGA.
The simulation estimated that 5,965 infants (95% UI: 5,415–6,515) are born alive with at 
least one nonsyndromic CCHD annually in the United States, with TOF, COA/IAA, d-TGA 
and HLHS accounting for ~75% of all liveborn CCHD cases (Table 2). Excluding CCHD 
cases estimated to be detected prenatally (n=1,800 overall), an estimated 2,410 CCHD (95% 
UI: 2,150–2,680) would receive a timely diagnosis and 1,755 CCHD cases (95% UI: 1,540–
1,980) would be detected “late” (at > 3 days of birth) and be most likely to benefit from 
CCHD screening through pulse oximetry; infants with COA/IAA accounted for 
approximately half of late detected cases.
After accounting for the estimates of CCHD screening sensitivity using pulse oximetry, we 
estimated that 875 (95% UI: 705–1,060) infants with CCHD in the U.S., including 470 (95% 
UI: 360–585) among primary CCHD screening targets alone, would be detected using 
CCHD screening through pulse oximetry (true positives) each year, corresponding to about 
15% of all CCHD cases (Figure 2). An additional 880 (95% UI: 700–1,080; 280 [95% UI: 
195–385] among primary screening targets alone) would be missed (false negatives), 
corresponding to about 15% of all CCHD cases (Figure 2). COA/IAA and TOF cases were 
the main contributors to both of these estimates. CCHD screening through pulse oximetry 
appears to offer the greatest benefit for infants with TAPVR, DORV, and COA/IAA; 20–
30% of cases of each of these defects were estimated to be detected through CCHD 
screening using pulse oximetry (Figure 2).
In our secondary analysis, under a scenario assuming “low” prenatal detection across the 
United States (19% across all CCHD types; eTable), we estimated that approximately 1,105 
(95% UI: 885–1,350) true positive and 1,020 (95% UI: 805–1,260) false negative CCHD 
cases would result from CCHD screening using pulse oximetry, corresponding to 
approximately 2.80 and 2.58 cases per 10,000 live births annually (Table 3). Comparatively, 
in a scenario assuming “high” prenatal detection (42% across all CCHD types; eTable), we 
estimated that approximately 740 (95% UI: 575–925) true positive and an additional 785 
(95% UI: 610–975) false negative CCHD cases would result from CCHD screening using 
pulse oximetry, corresponding to approximately 1.87 and 1.99 cases per 10,000 live births 
annually (Table 3).
DISCUSSION
We estimated that ~900 infants with nonsyndromic CCHD could be detected annually in the 
United States through universal implementation of CCHD screening using pulse oximetry. 
The majority of these infants would be those with CCHD less likely to be detected 
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prenatally or clinically at birth, such as COA/IAA, TOF, or d-TGA. These estimates were 
reassuring in that very few cases (0%–16% overall) of defects considered to be “primary” 
targets of CCHD screening were estimated to be false negatives. However, due to high birth 
prevalence, low prenatal detection rates, and limited CCHD screening sensitivity,14 an 
estimated ~900 infants with nonsyndromic CCHD, primarily those with COA/IAA, or TOF, 
were likely to be false negatives resulting from CCHD screening through pulse oximetry, 
suggesting that the sensitivity of CCHD screening in practice for all primary and secondary 
targets combined may be closer to 50% than the previous estimate of 76%.13 In our 
secondary analysis, despite the large difference in the proportion of infants with 
nonsyndromic CCHD identified prenatally under scenarios of “low” compared to “high” 
prenatal diagnosis prevalence (19% vs. 42%), the subsequent large difference in the number 
of infants with undiagnosed CCHD at birth was greatly diminished by “timely” diagnosis. 
Thus, the number of true positive nonsyndromic CCHD cases estimated to be identified by 
CCHD screening was relatively similar across the two prenatal screening scenarios (within 
~1 case per 10,000 live births), even though the relative difference was about 50%.
Our estimate of the number of infants with CCHD likely to be detected through screening 
(875 [95% UI: 705–1,060]) is similar to the 1,189 estimate from a recent cost effectiveness 
analysis.20 Differences may be attributable to the inclusion of infants with genetic 
syndromes in the cost effectiveness analysis or their use of overall estimates of prenatal 
diagnosis, late detection, and screening sensitivity for all CCHD combined rather than each 
specific CCHD type. Our estimate differs from that suggested by a report describing the first 
nine months of CCHD screening in New Jersey, the first state to mandate and implement 
state-wide CCHD screening, which found that three infants with CCHD were detected 
through screening alone.4 If extrapolated to the annual U.S. birth population, the New Jersey 
experience equates to approximately 220 CCHD cases,1 much lower than our estimate. One 
potential reason for this discrepancy may be differences in prenatal diagnosis prevalence. Of 
the 55 infants with CCHD identified in the NJ study, 48 (87%) were not reported as having a 
failed screen for a number of potential reasons, including having a prenatal diagnosis.4
In our analysis, a large proportion of nonsyndromic CCHD cases estimated to be both 
missed and detected through CCHD screening were infants with COA/IAA. As COA can 
have varying degrees of severity that may confer varying levels of hypoxia, it is possible 
that the more severe cases of coarctation are more likely to be detected prenatally or 
possibly identified through CCHD screening but less severe ones may be missed. 
Furthermore, unlike some previous studies of CCHD screening sensitivity,13,14 our CCHD 
definition allowed for diagnosis of CCHD within one year, rather than 28 days, of life, also 
potentially leading us to include less severe cases of COA. However, we were unable to 
examine the impact of severity of these lesions on the likelihood of being detected prenatally 
or through CCHD screening as information on severity was not available in our data 
sources.
While this analysis focused on CCHD cases likely to be detected and missed through 
universal CCHD screening, infants with non-CCHD conditions are likely to result in “false 
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positive” screens. In a meta-analysis of 13 studies of CCHD screening through pulse 
oximetry, Thangaratinam et al. (2012) estimated the false positive rate to be 0.14% (95% CI: 
0.06–0.33), which dropped to 0.05% (95% CI: 0.02–0.12) when screening was conducted at 
>24 hours after birth, the timeframe recommended by the AAP, AHA, and others.7,13 While 
infants with false positive screens do not have CCHD, they may have other clinically 
relevant conditions that contributed to their failed screening, including pneumonia and 
sepsis.4,21
Our analysis was subject to additional limitations. We restricted our estimates of birth 
prevalence, prenatal diagnosis, and late detection to 2000–2005 as we were only able to 
obtain maternal report of prenatal diagnosis through 2005 in the NBDPS.10 Our birth 
prevalence estimates were restricted to only the five central counties of metropolitan Atlanta 
and our prenatal diagnosis and late detection estimates were derived from a study conducted 
in 10 states, thus our estimates may not be reflective of the entire United States. Despite 
potential improvements in prenatal diagnosis over time22 and differing definitions of 
prenatal diagnosis, our range of prenatal diagnosis estimates from 2000–2005 NBDPS data 
were consistent with those from a study using national 2006–2012 Society of Thoracic 
Surgeons data23, and our “high” prenatal diagnosis estimates were similar to a recent 
analysis of Massachusetts data.22 Our definition of late detected CCHD was based on the 
timing of the first documented echocardiography confirming the defect, not necessarily the 
first time echocardiography was ever performed, thus some infants may have been 
misclassified. However, our overall estimate of late detection is similar to that of a study of 
a cohort of Florida births, in which the authors defined late detection as diagnosis after birth 
hospitalization.9 Additionally, it is possible that some infants that we classified as having 
“timely” diagnosis could still have benefited from screening; thus, our estimates may be 
altered if screening is performed earlier. An additional limitation is that we relied on 
published estimates of CCHD-specific screening sensitivity that included studies with 
screening algorithms different from that recommended by the AAP, AHA, and others and 
we were unable to assess the impact of these differences, such as the age at screening, in our 
study. It is possible that classification of specific defects differed across our other data 
sources (MACDP, NBDPS, Prudhoe et al.). Finally, our estimates of the number of infants 
potentially detected through CCHD screening only apply to the subset of infants, estimated 
to be approximately 88%,15 with CCHD not associated with a genetic syndrome.
In the absence of national implementation and data collection on CCHD screening, our 
analysis used modeling approaches to estimate the potential impact of screening and had 
several strengths making it a valuable contribution to the literature. We used data from a 
population-based active surveillance system to estimate CCHD prevalence and a population-
based case-control study to estimate prenatal diagnosis and late detection. To better account 
for uncertainty, we used a range of estimates for our model parameters (typically the mean 
and standard error). Additionally, estimates from our secondary analysis allow public health 
professionals and policy makers to consider the prevalence of prenatal diagnosis in their 
communities when estimating the likely impact of CCHD screening.
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Based on our model, nearly 900 infants per year with nonsyndromic CCHD are likely to be 
detected through universal CCHD screening in the United States; however, an equal number 
are likely to be missed. While many infants with CCHD will likely be identified through 
screening, there will still be many false negatives, suggesting that the general practitioner 
should not rely on CCHD screening alone to rule out a CCHD.25 Our analysis also suggests 
that increases in prenatal diagnosis of CCHD are unlikely to substantially impact the number 
of infants detected through CCHD screening. Future efforts should focus on documenting 
the true impact of CCHD screening in practice, and linking CCHD screening data with birth 
defects surveillance data,24 in order to identify the outcome of infants with false negative 
screening results.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Funding source: This work was partially supported through cooperative agreements under PA 96043, PA 02081 
and FOA DD09-001 from the Centers for Disease Control and Prevention.
REFERENCES
1. Mahle WT, Newburger JW, Matherne GP, et al. Role of pulse oximetry in examining newborns for 
congenital heart disease: A scientific statement from the AHA and AAP. Pediatrics. 2009; 124(2):
823–836. [PubMed: 19581259] 
2. Secretary's Advisory Committe on Heritable Disorders in Newborns and Children. HHS Secretary 
adopts recommendation to add critical congenital heart disease to the Recommended Uniform 
Screening Panel. September 21, 2011. Available from: http://www.HRSA.Gov/advisorycommittees/
mchbadvisory/heritabledisorders/recommendations/correspondence/
cyanoticheartsecre09212011.pdf. 
3. Centers for Disease Control Prevention. Assessment of current practices and feasibility of routine 
screening for critical congenital heart defects � Georgia, 2012. MMWR Morb Mortal Wkly Rep. 
2013; 62(15):288–291. [PubMed: 23594685] 
4. Garg LF, Van Naarden Braun K, Knapp MM, et al. Results from the New Jersey statewide critical 
congenital heart defects screening program. Pediatrics. 2013; 132(2):e314–e323. [PubMed: 
23858425] 
5. American Academy of Pediatrics Division of State Government Affairs. CCHD screening map. 
http://www.Cqstatetrack.Com/texis/viewrpt/main.Html?Event=4f7f371574&run=y. 
6. Walsh W. Evaluation of pulse oximetry screening in middle Tennessee: Cases for consideration 
before universal screening. J Perinatol. 2011; 31(2):125–129. [PubMed: 20508595] 
7. Kemper AR, Mahle WT, Martin GR, et al. Strategies for implementing screening for critical 
congenital heart disease. Pediatrics. 2011; 128(5):e1259–e1267. [PubMed: 21987707] 
8. Peterson C, Ailes E, Riehle-Colarusso T, et al. Late detection of critical congenital heart disease 
among us infants: Estimation of the potential impact of proposed universal screening using pulse 
oximetry. JAMA Pediatr. 2014; 168(4):361–370. [PubMed: 24493342] 
9. Peterson C, Dawson A, Grosse SD, et al. Hospitalizations, costs, and mortality among infants with 
critical congenital heart disease: How important is timely detection? Birth Defects Res A Clin Mol 
Teratol. 2013; 97(10):664–672. [PubMed: 24000201] 
10. Ailes EC, Gilboa SM, Riehle-Colarusso T, et al. Prenatal diagnosis of nonsyndromic congenital 
heart defects. Prenat Diagn. 2013; 34(3):214–222. [PubMed: 24222433] 
Ailes et al. Page 8













11. Friedberg MK, Silverman NH, Moon-Grady AJ, et al. Prenatal detection of congenital heart 
disease. The Journal of Pediatrics. 2009; 155(1):26–31. [PubMed: 19394031] 
12. Pinto NM, Keenan HT, Minich LL, Puchalski MD, Heywood M, Botto LD. Barriers to prenatal 
detection of congenital heart disease: A population based study. Ultrasound Obstet Gynecol. 2012; 
40(4):418–425. [PubMed: 21998002] 
13. Thangaratinam S, Brown K, Zamora J, Khan KS, Ewer AK. Accuracy of pulse oximetry in 
screening for congenital heart disease in asymptomatic newborns: A systematic review. Lancet. 
2012; 92(3):F176–F180.
14. Prudhoe S, Abu-Harb M, Richmond S, Wren C. Neonatal screening for critical cardiovascular 
anomalies using pulse oximetry. Arch Dis Child Fetal Neonatal Ed. 2013; 98(4):F346–F350. 
[PubMed: 23341250] 
15. Oster ME, Lee KA, Honein MA, Riehle-Colarusso T, Shin M, Correa A. Temporal trends in 
survival among infants with critical congenital heart defects. Pediatrics. 2013; 131(5):e1502–
e1508. [PubMed: 23610203] 
16. Correa A, Cragan JD, Kucik JE, et al. Reporting birth defects surveillance data 1968–2003. Birth 
Defects Res A Clin Mol Teratol. 2007; 79(2):65–186. [PubMed: 17278144] 
17. Riehle-Colarusso T, Strickland MJ, Reller MD, et al. Improving the quality of surveillance data on 
congenital heart defects in the Metropolitan Atlanta Congenital Defects Program. Birth Defects 
Res A Clin Mol Teratol. 2007; 79(11):743–753. [PubMed: 17990334] 
18. Yoon PW, Rasmussen SA, Lynberg MC, et al. The National Birth Defects Prevention Study. 
Public Health Rep. 2001; 116(Suppl 1):32–40. [PubMed: 11889273] 
19. Botto LD, Lin AE, Riehle-Colarusso T, Malik S, Correa A. National Birth Defects Prevention 
Study. Seeking causes: Classifying and evaluating congenital heart defects in etiologic studies. 
Birth Defects Res A Clin Mol Teratol. 2007; 79(10):714–727. [PubMed: 17729292] 
20. Peterson C, Grosse S, Oster M, Olney R, Cassell C. Cost-effectiveness of routine screening for 
critical congenital heart disease in us newborns. Pediatrics. 2013; 132(3):e595–e603. [PubMed: 
23918890] 
21. Ewer AK, Middleton LJ, Furmston AT, et al. Pulse oximetry screening for congenital heart defects 
in newborn infants (pulseox): A test accuracy study. Lancet. 2011; 378(9793):785–794. [PubMed: 
21820732] 
22. Liberman RF, Getz KD, Lin AE, et al. Delayed diagnosis of critical congenital heart defects: 
Trends and associated factors. Pediatrics. 2014; 134(2):e373–e381. [PubMed: 25070301] 
23. Quartermain, M.; Pasquali, SP.; Hill, K., et al. National variation in prenatal diagnosis of 
congenital heart disease by state and lesion type: An analysis of the society of thoracic surgeons 
congenital heart surgery database. Paper presented at: American College of Cardiology; 2014. 
24. Olney RS, Botto LD. Newborn screening for critical congenital heart disease: Essential public 
health roles for birth defects monitoring programs. Birth Defects Res A Clin Mol Teratol. 2012; 
94(12):965–969. [PubMed: 23184496] 
25. Oster ME, Colarusso T, Glidewell J. Screening for Critical Congenital Heart Disease: A Matter of 
Sensitivity. Pediatr Cardiol. 2013; 34:203–204. [PubMed: 23179425] 
26. Hamilton B, Martin J, Ventura S. Births: Preliminary data for 2012. National Vital Statistics 
Reports. 2013; 68(3)
Abbreviations
AAP American Academy of Pediatrics
AHA American Heart Association
COA coarctation of the aorta
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DORV double-outlet right ventricle
HLHS hypoplastic left heart syndrome
IAA interrupted aortic arch
MACDP Metropolitan Atlanta Congenital Defects Program
NBDPS National Birth Defects Prevention Study
TOF tetralogy of Fallot
TAPVR total anomalous pulmonary venous return
UI uncertainty interval
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What’s Known on This Subject
Newborn screening for critical congenital heart defects (CCHD) has been implemented in 
many hospitals, yet there is uncertainty about the number of infants with CCHD that 
might be detected through universal implementation of newborn CCHD screening in the 
United States.
What This Study Adds
We estimated that ~875 infants with CCHD might be detected, and ~880 missed, 
annually through universal CCHD screening in the United States. Increases in prenatal 
diagnosis are unlikely to substantially impact the number of infants detected through 
CCHD screening.
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Model estimating the number of U.S. nonsyndromic critical congenital heart defect (CCHD) 
cases in 2012 estimated to be born alive, prenatally diagnosed, born undiagnosed, timely 
detected, late detected, and false negatives and true positives of CCHD screening through 
pulse oximetry, assuming universal implementation of CCHD screening in all states
Notes: CCHD=critical congenital heart defects
Ailes et al. Page 12














Proportion of U.S. nonsyndromic critical congenital heart defect (CCHD) cases in 2012 
estimated to be prenatally diagnosed, timely detected, and true positive, and false negative 
of CCHD screening through pulse oximetry, by CCHD type, assuming universal 
implementation of CCHD screening in all states
Notes: CCHD=critical congenital heart defects; HLHS=hypoplastic left heart syndrome; d-
TGA=dextro-transposition of the great arteries; TOF=tetralogy of Fallot; TAPVR=total 
anomalous pulmonary venous return; DORV=double outlet right ventricle; COA/
IAA=coarctation of the aorta/interrupted aortic arch; Multiple=Multiple critical congenital 
heart defects
Ailes et al. Page 13
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